Beat Hauenstein assumes new responsibilities as CEO of Oettinger Davidoff AG. Photo: Oettinger Davidoff
On Friday, August 25th, the Oettinger Davidoff Board has appointed Mr Beat Hauenstein, the former COO, as new CEO of the Swiss family-owned company, effective immediately. Hans-Kristian Hoejsgaard has left the company. Mr Domenico Scala has been appointed new president of the Board (succeeding Mr Andreas Schmid).
„This transition has been well arranged for quite a while“, Hans-Kristian Hoejsgaard said in a statement to Cigar Journal today. „After a fantastic seven years as CEO of this great company I would like to thank my team for all their hard work, and of course I wish my successor Beat Hauenstein all the best.“
The official press release issued by the company on Monday morning states:
After ten years on the Board of Directors of Oettinger Davidoff AG, Andreas Schmid (60), company Chairman and shareholder, will leave the company in order to concentrate on his other roles at various globally active firms and on his own business activities. The Board of Directors of Oettinger Davidoff AG has nominated Domenico Scala (52) as the new Chairman.
As part of the ongoing rejuvenation of the operational management, the Board of Directors has also appointed Beat Hauenstein (50), former COO of the Group, as the new CEO. Hauenstein succeeds Hans-Kristian Hoejsgaard (59), who has decided to leave the company he has led for seven years in order to concentrate on his board and consultancy mandates outside the company. The Board of Directors would like to thank Andreas Schmid and Hans-Kristian Hoejsgaard for their many years of successful work for the company, and wishes both of them all the best for their personal and professional future.
About Beat Hauenstein
Beat Hauenstein joined Oettinger Davidoff in 2003 as CIO. From 2008 to 2015 he assumed the role of SVP Global Operations followed by the position of COO in 2016. In September 2017, Hauenstein was named CEO of the company.
About Domenico Scala
Domenico Scala was responsible as CFO of Syngenta and CEO of Nobel Biocare. Until May 2016, he chaired the independent Audit & Compliance Committee of FIFA. Currently, he is the Chairman of Basilea Pharmaceutica, BAK Basel Economics as well as the President of BaselArea, a Member of the Board of Overseers of Tufts University in Boston and a member of the Bank Council of Basler Kantonalbank.
